William J Catalona, MD Comments on the USPSTF recommendation against prostate-specific antigen (PSA)-based screening

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
DRAFT
Summary of Recommendation and Evidence
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)-based screening for prostate cancer. This is a grade D recommendation.
This recommendation applies to men in the U.S. population that do not have symptoms that are highly suspicious for prostate cancer, regardless of age, race, or family history. The Task Force did not evaluate the use of the PSA test as part of a diagnostic strategy in men with symptoms that are highly suspicious for prostate cancer. This recommendation also does not consider the use of the PSA test for surveillance after diagnosis and/or treatment of prostate cancer. The full text of the draft recommendation can be viewed here  .
The USPSTF called for comments on it’s draft recommendation here .

Below are the comments of William J. Catalona, MD.
Dr. Catalona is Professor of Urology at Northwestern